Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 4/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243526 | 0.84 | HRH3 (0.57) | PNMTHTR2CHTR2BTPSAB1HRH3 | |
| SCHEMBL17258825 | 0.79 | PNMT (0.57) | PNMTHTR2CHTR2BTPSAB1HRH3 | |
| SCHEMBL1243584 | 0.77 | PNMT (0.55) | PNMTHTR2CHTR2BTPSAB1 | |
| SCHEMBL2403756 | 0.77 | PNMT (0.53) | PNMTHTR2CHTR2BTPSAB1TSHR | |
| SCHEMBL1241177 | 0.77 | PNMT (0.53) | PNMTHTR2CHTR2BTPSAB1TSHR | |
| SCHEMBL1242901 | 0.77 | POLB (0.60) | PNMTHTR2CHTR2BTPSAB1HRH3 | |
| Hydrochloric Acid SCHEMBL1242900 | 0.77 | PNMT (0.52) | PNMTHTR2CHTR2BTPSAB1TSHR | |
| Hydrochloric Acid SCHEMBL2405913 | 0.77 | PNMT (0.52) | PNMTHTR2CHTR2BTPSAB1TSHR | |
| SCHEMBL1243393 | 0.75 | TPSAB1 (0.51) | PNMTHTR2CHTR2BTPSAB1HRH3 | |
| SCHEMBL1244028 | 0.75 | PNMT (0.61) | PNMTHTR2CHTR2BTPSAB1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | claimed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | BACE1, SLC6A2, KCNQ2 | PNMT 30/4885HTR2C 23/4885HTR2B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.